Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
by on Monday, August 8th, 2011 | No Comments
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsor: Bayer
Recruiting – verified August 2011
Excerpt from: Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan